glp-1 agonist pregnancy Should receptor agonists be continued into early pregnancy?⁠ ⁠ ➡️ Swipe to read the key takeaways from a recent target trial emulation study on first-trimester GLP-1 receptor use and Discontinuing GLP-1 Receptor Agonist Use

--- Track Your Peptide Protocol Running GHK-Cu alongside other compounds like BPC-157, Retatrutide, or Tesamorelin

According to a comprehensive aggregation of all the scientific data on BPC-157 to date, the following benefits have been observed in rats [2]: Exerts protective effects during damaging surgical procedures or administration of a toxic substance Heals organ, bone, and joint damage Treats stomach ulcers Possesses anti-inflammatory properties While the side effects of BPC-157 appear to be non-existent, very little research involving human test subjects exists [3]: While BPC-157 is not approved by the FDA, it can be purchased by researchers and, in rare cases, can be prescribed by a doctor in certain circumstances

Plasma concentrations of GLP-1 and GIP are very low in the fasting state and increase 1530 min after ingestion

Pro Tip Run a monthly denial analysis filtered by CPT 96372